Leerink Partnrs Has Strong Estimate for ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Leerink Partnrs upped their FY2024 earnings estimates for Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($2.35) for the year, up from their prior estimate of ($2.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.68) EPS, FY2025 earnings at ($2.01) EPS, FY2026 earnings at ($1.82) EPS and FY2027 earnings at ($1.76) EPS.

A number of other research firms have also weighed in on ZNTL. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim lowered their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. HC Wainwright reduced their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Finally, Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Down 3.0 %

Zentalis Pharmaceuticals stock opened at $1.63 on Monday. The stock has a 50-day moving average price of $2.87 and a 200 day moving average price of $3.23. The company has a market capitalization of $116.16 million, a price-to-earnings ratio of -0.65 and a beta of 1.86. Zentalis Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Ieq Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth $46,000. Savant Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $72,000. SG Americas Securities LLC lifted its position in Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after acquiring an additional 30,240 shares during the period. Barclays PLC boosted its holdings in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in Zentalis Pharmaceuticals by 8.7% in the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after buying an additional 15,597 shares in the last quarter.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.60% of the stock is owned by corporate insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.